DE60313437D1 - Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 - Google Patents

Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4

Info

Publication number
DE60313437D1
DE60313437D1 DE60313437T DE60313437T DE60313437D1 DE 60313437 D1 DE60313437 D1 DE 60313437D1 DE 60313437 T DE60313437 T DE 60313437T DE 60313437 T DE60313437 T DE 60313437T DE 60313437 D1 DE60313437 D1 DE 60313437D1
Authority
DE
Germany
Prior art keywords
seq
amino acid
acid sequence
sequence shown
mhc class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313437T
Other languages
English (en)
Other versions
DE60313437T2 (de
Inventor
Miles Carroll
Susan Kingsman
Irina Redchenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idm S A
Oxford Biomedica UK Ltd
Original Assignee
Idm S A
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idm S A, Oxford Biomedica UK Ltd filed Critical Idm S A
Publication of DE60313437D1 publication Critical patent/DE60313437D1/de
Application granted granted Critical
Publication of DE60313437T2 publication Critical patent/DE60313437T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60313437T 2002-02-13 2003-02-13 Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 Expired - Lifetime DE60313437T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0203419.7A GB0203419D0 (en) 2002-02-13 2002-02-13 Peptide
GB0203419 2002-02-13
PCT/GB2003/000670 WO2003068816A1 (en) 2002-02-13 2003-02-13 Mhc class i peptide epitopes from the human 5t4 tumor-associated antigen

Publications (2)

Publication Number Publication Date
DE60313437D1 true DE60313437D1 (de) 2007-06-06
DE60313437T2 DE60313437T2 (de) 2008-01-03

Family

ID=9931004

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313437T Expired - Lifetime DE60313437T2 (de) 2002-02-13 2003-02-13 Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4

Country Status (9)

Country Link
US (3) US7575916B2 (de)
EP (1) EP1476463B1 (de)
JP (1) JP4533630B2 (de)
AT (1) ATE360642T1 (de)
AU (1) AU2003207321B2 (de)
CA (1) CA2476165A1 (de)
DE (1) DE60313437T2 (de)
GB (1) GB0203419D0 (de)
WO (1) WO2003068816A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
AU2003259913A1 (en) * 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP4926168B2 (ja) * 2005-05-13 2012-05-09 オックスフォード バイオメディカ（ユーケー）リミテッド ペプチド
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
WO2007062371A2 (en) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Live vector vaccine and uses thereof
AU2007226696C1 (en) * 2006-03-10 2016-02-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
WO2008059252A2 (en) * 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
ES2535613T3 (es) 2008-07-15 2015-05-13 Oxford Biomedica (Uk) Limited Método inmunoterapéutico
GB201807932D0 (en) * 2018-05-16 2018-06-27 Redchenko Irina Compositions and methods for inducing an immune response
FR3119325B1 (fr) 2021-01-29 2023-08-11 Renault Jean Yves Compositions liposomales orales

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795954B2 (ja) 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
GB8305967D0 (en) 1983-03-04 1983-04-07 Univ Liverpool Material for treatment of spontaneous abortions
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
CA2089376C (en) 1990-08-13 2010-05-04 Phillip Dan Cook Sugar modified oligonucleotides that detect and modulate gene expression
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
NZ503318A (en) 1997-09-23 2001-11-30 Oxford Biomedica Ltd Modified haemopoietic stem cell comprised of a spliced upstream with a nucleotide sequence of interest to be used as in gene therapy
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
EP2042598A1 (de) 1998-11-18 2009-04-01 Oxford Biomedica (UK) Limited Verwendung vom Krebs-assoziierten Antigen 5T4 zur Immuntherapie
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
WO2002038612A2 (en) 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide

Also Published As

Publication number Publication date
US20110165668A1 (en) 2011-07-07
GB0203419D0 (en) 2002-04-03
JP2006500903A (ja) 2006-01-12
US7888115B2 (en) 2011-02-15
AU2003207321A1 (en) 2003-09-04
EP1476463A1 (de) 2004-11-17
US20100086995A1 (en) 2010-04-08
AU2003207321B2 (en) 2009-01-29
ATE360642T1 (de) 2007-05-15
CA2476165A1 (en) 2003-08-21
JP4533630B2 (ja) 2010-09-01
WO2003068816A1 (en) 2003-08-21
EP1476463B1 (de) 2007-04-25
US20050123918A1 (en) 2005-06-09
DE60313437T2 (de) 2008-01-03
US7575916B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
PL378333A1 (pl) Sposoby profilaktyki i leczenia choroby Alzheimera (AD)
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
EP2258383A3 (de) Von der Telomerase abgeleitete antigene Peptide
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
RU2011105448A (ru) Применение ингибирующих tgf-бета1 пептидов для приготовления модулирующего иммунный ответ агента
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
DE60332425D1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
EP1536006A4 (de) Krebsantigene und deren nutzung
CA2337754A1 (en) Recombinant multivalent malarial vaccine against plasmodium falciparum
NZ526879A (en) Genes and proteins, and their use
EP2193804A3 (de) Rekombinantes Adenylat-Cyclase-Toxin von Bordetella induziert T-Zell-Antworten gegen tumorale Antigene
JP2007511534A5 (de)
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
DK0938329T3 (da) Immunogen TLP sammensætning
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
GB9400656D0 (en) The Vaccine and diagnostic test kit
HK1092162A1 (en) Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt)
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
Purton et al. Enhancing T cell memory: IL-7 as an adjuvant to boost memory T-cell generation
WO2007030771A4 (en) TARGETED IDENTIFICATION OF IMMUNOGENIC PEPTIDES
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften
FR2856598A1 (fr) Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
WO2001098363A3 (en) Peptides for use in the immunotherapy of renal cell carcinoma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition